Clarithromycin Attenuates the Bronchial Epithelial Damage Induced by Mycoplasma pneumoniae Infection


To analyze the bronchial epithelial cell damage induced by Mycoplasma pneumonia and the therapeutic effects of clarithromycin, we observed bronchial tissue damage by using a mouse model and performing immunostaining and scanning electron microscopy. The immunostaining study showed that M. pneumoniae-labeled fluorescence was found on the mucosal epithelium of mice, 6 days after inoculation. Clarithromycin treatment reduced the fluorescence. In this study, we demonstrated that the morphological alterations of bronchial mucosa, including the shortening and loss of ciliavisualized by scanning electron microscopy, and the inflammatory cell migration in the submucosal tissue visualized by differential interference contrast microscopy, were induced by mycoplasmal infection. We also showed that clarithromycin treatment, when administered from the first day of inoculation, attenuated both the bronchial epithelial damage and inflammatory cell migration in the submucosal tissue. These results suggest that the therapeutic effects of clarithromycin against mycoplasmal infection, may be due to its antibacterial and anti-inflammatory activities.

Share and Cite:

Tanaka, H. , Sadakata, H. , Nagami, T. , Miyazaki, S. , Tomita, T. , Shirata, S. and Yamagishi, T. (2014) Clarithromycin Attenuates the Bronchial Epithelial Damage Induced by Mycoplasma pneumoniae Infection. Advances in Microbiology, 4, 697-703. doi: 10.4236/aim.2014.411075.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Baseman, J.B., Reddy, S.P. and Dallo, S.F. (1996) Interplay between Mycoplasma Surface Proteins, Airway Cells, and the Protean Manifestations of Mycoplasma-Mediated Human Infections. American Journal of Respiratory and Critical Care Medicine, 154, S137-S144.
[2] Baseman, J.B. and Tully, J.G. (1997) Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety. Emerging Infectious Diseases, 3, 21-32.
[3] Waites, K.B. and Talkington, D.F. (2004) Mycoplasma pneumoniae and Its Role as Ahuman Pathogen. Clinical Microbiology Reviews, 17, 697-728.
[4] Carson, J.L., Collier, A.M. and Clyde Jr., W.A. (1979) Ciliary Membrane Alterations Occurring in Experimental Mycoplasma pneumoniae Infection. Science, 206, 349-351.
[5] Clyde Jr., W.A. (1979) Mycoplasma pneumoniae Infections of Man. In: Tully, J.G. and Whitcomb, R.F., Eds., The Mycoplasmas II. Human and Animal Mycoplasmas, Vol. II, Academic Press, New York, 275-306.
[6] Collier, A.M. and Baseman, J.B. (1973) Organ Culture Techniques with Mycoplasmas. Annals of the
New York Academy of Sciences, 225, 277-289.
[7] Shimizu, T., Kida, Y. and Kuwano, K. (2011) Cytoadherence-Dependent Induction of Inflammatory Responses by Mycoplasma pneumoniae. Immunology, 133, 51-61.
[8] Narita, M., Tanaka, H., Yamada, S., Abe, S., Ariga, T. and Sakiyama, Y. (2001) Significant Role of Interleukin-8 in Pathogenesis of Pulmonary Diseases Due to Mycoplasma pneumoniae Infection. Clinical and Diagnostic Laboratory Immunology, 8, 1028-1030.
[9] Tanaka, H., Narita, M., Teramoto, S., Saikai, T., Oashi, K., Igarashi, T. and Abe, S. (2002) Role of Interleukin-18 and T-Helper Type 1 Cytokines in the Development of Mycoplasma pneumoiniae Pneumonia in Adults. Chest, 121, 1493-1497.
[10] Kikuchi, T., Hagiwara, K., Honda, Y., Gomi, K., Kobayashi, T., Takahashi, H., Tokue, Y., Watanabe, A. and Nukiwa, T. (2002) Clarithromycin Suppresses Lipopolysaccharide-Induced Interleukin-8 Production by Human Monocytes through AP-1 and NF-Kappa B Transcription Factors. Journal of Antimicrobial Chemotherapy, 49, 745-755.
[11] Kohyama, T., Takizawa. H., Kawasaki, S., Akiyama, N., Sato, M. and Ito, K. (1999) Fourteen-Member Macrolides Inhibit Interleukin-8 Release by Human Eosinophils from Atopic Donors. Antimicrobial Agents and Chemotherapy, 43, 907-911.
[12] Labro, M.T. (1998) Anti-Inflammatory Activity of Macrolides: A New Therapeutic Potential? Journal of Antimicrobial Chemotherapy, 41, 37-46.
[13] Tagliabue, C., Techasaensiri, C., Torres, J.P., Katz, K., Meek, C., Kannan, T.R., Coalson, J.J., Esposito, S., Principi, N., Leff, R., Baseman, J.B. and Hardy, R.D. (2011) Efficacy of Increasing Dosages of Clarithromycin for Treatment of Experimental Mycoplasma pneumonia Pneumonia. Journal of Antimicrobial Chemotherapy, 66, 2323-2329.
[14] Tryon, V.V. and Baseman, J.B. (1992) Pathogenic Determinants and Mechanisms. In: Maniloff, J., Ed., Mycoplasmas: Molecular Biology and Pathogenesis, American Society for Microbiology, Washington DC, 457-471.
[15] Kannan, T.R. and Baseman, J.B. (2006) ADP-Ribosylating and Vacuolating Cytotoxin of Mycoplasma pneumoniae Represents Unique Virulence Determinant among Bacterial Pathogens. Proceedings of the National Academy of Sciences of the United States of America, 103, 6724-6729.
[16] Tamaoki, J., Chiyotani, A., Sakai, N., Takeyama, K. and Takizawa, T. (1992) Effect of Erythromycin on Ciliary Motility in Rabbit Airway Epithelium in Vitro. Journal of Antimicrobial Chemotherapy, 29, 173-178.
[17] Kurata, S., Taguchi, H., Sasaki, T., Fujioka, Y. and Kamiya, S. (2010) Antimicrobial and Immunomodulating Effect of Clarithromycinon Macrolide-Resistant Mycoplasma pneumoniae. Journal of Medical Microbiology, 59, 693-701.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.